Table 1.

Study population characteristics

Serum available (N = 495)Serum not available (N = 92)
Men440 (88.9%)73 (79.4%)
Age63.2 ± 11.064.8 ± 10.9
Race
 White461 (93.1%)85 (92.4%)
 Black2 (0.4%)
 Hispanic6 (1.2%)2 (2.2%)
 Asian4 (0.8%)
 Native American5 (1.0%)1 (1.1%)
Former smoker313 (63.2%)62 (67.4%)
Current smoker73 (14.8%)13 (14.2%)
BMI (kg/m2)27.4 ± 5.027.9 ± 5.9
Stage
 Lymph node negative (I–IIA)157 (31.7%)30 (32.6%)
 Lymph node positive (IIA–IVA)240 (48.5%)48 (52.2%)
 Metastatic (IVB)98 (19.8%)14 (15.2%)
Treatmenta
 Surgery358 (72.3%)66 (71.7%)
 Chemotherapy392 (79.2%)66 (71.7%)
 Radiation351 (70.9%)60 (65.2%)
25(OH)D (ng/mL)20.7 ± 10.2
Death377 (76.2%)62 (67.4%)
  • NOTE: Values represent number (%) or mean ± SD.

  • aTreatment values are not mutually exclusive. One patient with vitamin D available was missing information on treatment. Among participants with serum available, information was missing about race (n = 16), smoking status (n = 3), BMI (n = 18), and treatment modality (n = 1). Among participants with serum not available, information was missing about race (n = 4) and BMI (n = 2).